...
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment
【24h】

Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment

机译:接受辅助性FEC-D治疗的早期乳腺癌患者的发热性中性粒细胞减少症的发生率

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study is to determine the incidence of febrile neutropenia (FN) among women receiving FEC-D (flurouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2) every 3 weeks for three cycles followed by docetaxel 100 mg/m(2) every 3 weeks for three cycles) chemotherapy for early stage breast cancer (ESBC) and the impact of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis in a non-clinical trial setting.
机译:这项研究的目的是确定接受FEC-D(氟尿嘧啶500 mg / m(2),表柔比星100 mg / m(2)和环磷酰胺500 mg / m(2))的女性的发热性中性粒细胞减少症(FN)的发生率每三个星期进行三个周期的多西他赛治疗,然后每三个星期进行三周期多西紫杉醇100 mg / m(2))早期乳腺癌(ESBC)的化学疗法以及原发性粒细胞集落刺激因子(G-CSF)预防的影响非临床试验设置。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号